Zoetis Inc. (NYSE:ZTS) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 33.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 381,016 shares of the company’s stock after selling 187,456 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Zoetis were worth $62,734,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in Zoetis during the fourth quarter worth about $44,000. Sound Income Strategies LLC boosted its holdings in Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company’s stock valued at $46,000 after purchasing an additional 164 shares during the last quarter. Finally, Bfsg LLC grew its stake in shares of Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company’s stock valued at $48,000 after buying an additional 252 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on ZTS. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. UBS Group lowered their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $212.13.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president now directly owns 15,129 shares of the company’s stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is owned by insiders.

Zoetis Stock Performance

Shares of Zoetis stock opened at $156.01 on Friday. The stock has a market capitalization of $69.46 billion, a price-to-earnings ratio of 28.01, a price-to-earnings-growth ratio of 2.61 and a beta of 0.94. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The business has a 50-day moving average of $160.25 and a 200 day moving average of $162.87. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same period last year, the firm earned $1.38 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis’s dividend payout ratio (DPR) is 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.